Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Lopez-Acevedo, M, Lowery, WJ, Lowery, AW, Lee, PS, and Havrilesky, LJ. "Palliative and hospice care in gynecologic cancer: a review." Gynecol Oncol 131, no. 1 (October 2013): 215-221. (Review)

Full Text

Tergas, AI, Havrilesky, LJ, Fader, AN, Guntupalli, SR, Huh, WK, Massad, LS, and Rimel, BJ. "Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer." Gynecol Oncol 130, no. 3 (September 2013): 421-425.

Full Text

Lowery, WJ, Lowery, AW, Barnett, JC, Lopez-Acevedo, M, Lee, PS, Secord, AA, and Havrilesky, L. "Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer." Gynecol Oncol 130, no. 3 (September 2013): 426-430.

Full Text

Phippen, NT, Leath, CA, Miller, CR, Lowery, WJ, Havrilesky, LJ, and Barnett, JC. "Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?." Gynecol Oncol 130, no. 2 (August 2013): 317-322.

Full Text

Peragallo Urrutia, R, Coeytaux, RR, McBroom, AJ, Gierisch, JM, Havrilesky, LJ, Moorman, PG, Lowery, WJ, Dinan, M, Hasselblad, V, Sanders, GD, and Myers, ER. "Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis." Obstetrics and gynecology 122, no. 2 Pt 1 (August 1, 2013): 380-389. (Review)

Scholars@Duke

Peragallo Urrutia, R, Coeytaux, RR, McBroom, AJ, Gierisch, JM, Havrilesky, LJ, Moorman, PG, Lowery, WJ, Dinan, M, Hasselblad, V, Sanders, GD, and Myers, ER. "Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis." Obstet Gynecol 122, no. 2 Pt 1 (August 2013): 380-389. (Review)

Full Text

Wenham, RM, Lapolla, J, Lin, H-Y, Apte, SM, Lancaster, JM, Judson, PL, Gonzalez-Bosquet, J, Herschberger, A, Havrilesky, LJ, and Secord, AA. "A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy." Gynecol Oncol 130, no. 1 (July 2013): 19-24.

Full Text

Havrilesky, LJ, Moorman, PG, Lowery, WJ, Gierisch, JM, Coeytaux, RR, Urrutia, RP, Dinan, M, McBroom, AJ, Hasselblad, V, Sanders, GD, and Myers, ER. "Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis." Obstet Gynecol 122, no. 1 (July 2013): 139-147. (Review)

Full Text

Jewell, EL, Smrtka, M, Broadwater, G, Valea, F, Davis, DM, Nolte, KC, Valea, R, Myers, ER, and Havrilesky, LJ. "Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers." Int J Gynecol Cancer 23, no. 6 (July 2013): 1158-1166.

Full Text

Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Alvarez Secord, A, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecol Oncol 130, no. 1 (July 2013): 156-161.

Full Text

Pages